Canaccord Genuity Maintains Buy on Taysha Gene Therapies, Lowers Price Target to $6
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst Whitney Ijem maintains a Buy rating on Taysha Gene Therapies (NASDAQ:TSHA) but lowers the price target from $7 to $6.
August 14, 2024 | 12:16 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Taysha Gene Therapies but lowers the price target from $7 to $6.
The Buy rating suggests continued confidence in the company's prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100